ALNY News and Press, Alnylam Pharmaceuticals Inc. From 04/26/23

– Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date – – Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing ...

- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date - - R...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Management will provide an update on the C...

2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...

2023-04-13 05:02:47 ET A federal appeals court blocked part of a Texas court's ruling that would halt the access to the abortion pill mifepristone. Earlier this week, the U.S. Justice Department (DOJ) had asked the U.S. 5th Circuit Court of Appeals to halt U.S. Judge Matthew Kacsmar...

2023-04-12 12:09:05 ET Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) jumped ~11% Wednesday after SVB Securities upgraded the RNAi therapeutics company to Outperform from Market Perform, citing an attractive risk-reward setup following the recent selloff. The analyst Mani Forooh...

2023-04-10 10:48:10 ET A group of senior pharma executives, including Pfizer ( NYSE: PFE ) chief executive Albert Bourla, has come forward in support of the FDA after a Texas-based judge suspended the approval of abortion treatment mifepristone on Friday. Mifepristone, appro...

2023-03-22 13:30:00 ET Summary For many investors, the search to find growth - the next Apple, Microsoft, or Amazon - is the holy grail of investing. At the same time, this is easier said than done. In this article, I take a look at an ETF that offers a structured attempt at doing...

2023-03-22 08:51:49 ET Summary Shares of infectious disease medicines concern Vir Biotechnology are trading at only a $6-$7 per share premium to cash as the revenue from its Covid-19 medication dries up. The company has three compounds undergoing evaluation as both monotherapies a...